- Report
- March 2024
- 192 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- February 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- May 2024
- 268 Pages
Global
From €5237EUR$5,450USD£4,495GBP
- Report
- January 2024
- 148 Pages
Global
From €3746EUR$3,899USD£3,216GBP
- Report
- November 2023
- 190 Pages
Global
From €4708EUR$4,900USD£4,042GBP
- Report
- May 2024
- 262 Pages
From €5381EUR$5,600USD£4,619GBP
- Report
- January 2022
- 115 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Report
- June 2021
- 54 Pages
Global
€21139EUR$22,000USD£18,146GBP
- Report
- February 2024
- 90 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- August 2023
- 110 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- August 2023
- 96 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- August 2023
- 86 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- March 2022
- 124 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Book
- June 2015
- 392 Pages
The H1N1 Vaccine is a vaccine developed to protect against the H1N1 strain of influenza, also known as swine flu. It is a type of inactivated vaccine, meaning it contains killed virus particles that are unable to cause infection. The vaccine is administered through injection and is recommended for people of all ages. It is especially important for those at high risk of complications from the virus, such as pregnant women, young children, and people with weakened immune systems.
The H1N1 Vaccine market is a subset of the larger Vaccines market, which includes a wide range of products designed to protect against infectious diseases. Vaccines are an important tool in public health, as they can help reduce the spread of disease and protect vulnerable populations.
Some companies in the H1N1 Vaccine market include Sanofi Pasteur, GlaxoSmithKline, Merck, and Pfizer. Show Less Read more
